Every 8-K that Hinge Health, Inc. (HNGE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow HNGE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HNGE filings page.
Hinge Health, Inc. (HNGE) entered into a long-term office lease with 50 Beale Street LLC for approximately 119,278 rentable square feet at 300 Mission Street, San Francisco. The lease is expected to commence five business days after the August 18, 2026 execution date and is anticipated to expire on February 28, 2037.
Over the lease term, aggregate estimated base rent payments total approximately $86.0 million, with Hinge Health also responsible for its share of operating expenses, taxes, insurance, and other costs. The landlord will provide a $17.9 million tenant improvement allowance, and Hinge Health must post an $2.8 million irrevocable standby letter of credit. The lease includes one five-year renewal option and a one-time early termination right effective January 31, 2035, subject to conditions, including payment of a termination amount. The lease creates a direct financial obligation for the company.
Hinge Health, Inc. reported a strong second quarter for 2026, with revenue of $212.8 million, an increase of 53% year-over-year. GAAP income from operations was $40.4 million, compared with a GAAP operating loss of $580.7 million a year earlier, and non-GAAP income from operations rose to $61.5 million with a 29% non-GAAP operating margin. GAAP diluted net income per share was $0.52, while non-GAAP diluted net income per share was $0.59. Free cash flow reached $99.6 million, and cash, cash equivalents, marketable securities and restricted cash totaled $475.6 million as of June 30, 2026.
Management raised full-year 2026 guidance to $856–$860 million in revenue and $236–$244 million in non-GAAP income from operations, implying 46% and 101% year-over-year growth at the midpoints. The board expanded the share repurchase program to a total authorization of $496.5 million, leaving $300.0 million available for future repurchases. Hinge Health also signed a definitive agreement to acquire Cylinder Health, Inc. for $105 million in cash, aiming to enter gastrointestinal care with an integrated GI program expected to launch in 2027.
Hinge Health announced it will host its first Investor Day on June 10, 2026, alongside a significant raise to its 2026 outlook. For Q2 2026, the company now expects revenue between $200 million and $202 million, with year-over-year growth of 45% at the midpoint and non-GAAP operating margin of 25%.
For full year 2026, Hinge Health now guides to revenue of $818 million to $824 million, implying 40% year-over-year growth at the midpoint. Non-GAAP income from operations is projected between $217 million and $227 million, for a non-GAAP operating margin of 27% at the midpoint.
Hinge Health, Inc. held its 2026 annual stockholder meeting on June 3, 2026, where investors voted on board composition and the company’s auditor. The company’s multi-class structure gave one vote per Class A share, fifteen votes per Class B share, and votes for Series E preferred based on convertibility.
Stockholders elected Teddie Wardi to the board with 276,921,911 votes for and 14,888,631 votes withheld, and Tyler Sloat with 291,330,022 votes for and 480,520 votes withheld, plus 14,168,983 broker non-votes for each. They also ratified Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026, with 305,789,374 votes for, 121,058 against, and 69,093 abstentions.
Hinge Health, Inc. reported strong first quarter 2026 results with revenue of $182.3 million, up 47% from $123.8 million a year earlier, and GAAP gross margin improving to 85% from 81%.
GAAP income from operations rose to $32.1 million from $13.1 million, while GAAP diluted net income per share was $0.41 and non-GAAP diluted EPS was $0.45. Net cash provided by operating activities increased sharply to $43.1 million, driving free cash flow of $41.6 million. As of March 31, 2026, the company held $407.1 million in cash, cash equivalents, marketable securities and restricted cash.
Management raised full-year 2026 revenue guidance to a range of $798 million to $804 million, implying 36% year-over-year growth at the midpoint, and now expects non-GAAP operating margin of 26%. Hinge Health also highlighted 52% growth in last-12-months calculated billings to $769.9 million and a 23% increase in clients to 2,849.
Hinge Health, Inc. has appointed Tyler Sloat to its Board of Directors as a Class I director, effective March 16, 2026. His term runs until the company’s 2026 annual stockholders’ meeting, and he will serve as Chair of the Compensation Committee and a member of the Audit Committee.
Sloat is currently Chief Operating Officer and Chief Financial Officer of Freshworks Inc. and previously served as CFO of Zuora Inc. He will receive standard non-employee director compensation, including an initial grant of RSUs valued at $400,000 vesting over three years, annual cash retainers for his board and committee roles, and eligibility for future annual RSU awards.
Hinge Health, Inc. reported record fourth quarter and full-year 2025 results with rapid growth and improving profitability. Revenue rose 46% year over year in Q4 to $170.7 million, and 51% for 2025 to $587.9 million, as more employers and members adopted its digital musculoskeletal programs.
GAAP income from operations in Q4 increased to $27.3 million with an 84% gross margin, while non-GAAP income from operations reached $48.0 million. For 2025, non-GAAP income from operations was $119.5 million versus a loss in 2024, but GAAP loss from operations widened to $546.4 million largely due to $643.0 million of stock-based compensation.
Operating cash flow for 2025 grew to $171.4 million and free cash flow to $179.6 million, with cash, cash equivalents, marketable securities and restricted cash of $478.8 million at year-end. The company also repurchased $65.0 million of Class A common stock under a $250.0 million authorization and guided 2026 revenue to $732–$742 million with higher non-GAAP operating margins.
Hinge Health (HNGE) announced a share repurchase authorization. The Board approved a program to buy back up to $250.0 million of Class A common stock. The company disclosed that repurchases may occur in the open market, through privately negotiated transactions, or by other methods, and may be conducted in accordance with Rule 10b-18. The company may also use Rule 10b5-1 plans.
The authorization does not obligate Hinge Health to repurchase any specific amount and can be modified, suspended, or terminated at any time at the Board’s discretion. The company expects to fund repurchases with existing cash and cash equivalents and ongoing cash from operations.
Hinge Health, Inc. furnished an update announcing it issued a press release with financial results for the third quarter ended September 30, 2025, and will host a conference call on November 4, 2025 at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) to discuss the results.
The company noted that the press release and call reference non-GAAP financial measures, with reconciliations to GAAP provided in the press release. Hinge Health also posted supplemental investor materials on its investor relations website (ir.hingehealth.com) and stated it uses that site to disclose material information and comply with Regulation FD.
The information was furnished under Items 2.02 and 7.01, and the press release was included as Exhibit 99.1.
Hinge Health announced that certain lock-up restrictions tied to its IPO will partially terminate for a subset of holders. The company states that, following its Initial Earnings Release Date on August 5, 2025, the Early Release Condition was satisfied on August 6, 2025, triggering an early release provision in the lock-up agreements.
As a result, approximately 1.66 million Early Release Shares held by employees and service providers (25% of eligible securities owned as of March 1, 2025) will become eligible for immediate sale in the public market at the open of trading on August 19, 2025, subject to the Securities Act (including Rule 144 and Rule 701) and the company’s insider trading policy. All other shares remain subject to the original lock-up period that can extend up to 180 days after May 21, 2025.